242
Participants
Start Date
September 20, 2025
Primary Completion Date
May 31, 2028
Study Completion Date
May 31, 2030
toripalimab
Patients will receive toripalimab with a maximum treatment duration of one year (240 mg, IV drip, Q3W, for 16 cycles).
capecitabine
Patients will receive metronomic capecitabine, with a maximum treatment duration of one year (500 mg, twice daily, orally).
Sun Yat-sen University Cancer Center, Guangzhou
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Fifth Affiliated Hospital, Sun Yat-Sen University
OTHER
Zhongshan People's Hospital, Guangdong, China
OTHER
Sun Yat-sen University
OTHER